SCHEMBL7012946

SCHEMBL7012946

O=c1[nH]c2c(c(O)c1[N+](=O)[O-])CCCC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.47
ALOX15 P16050 1/20 0.47
LMNA P02545 2/20 0.44
GRIN2D O15399 8/20 0.43
GRIN3B O60391 8/20 0.43
GRIN1 Q05586 8/20 0.43
GRIN2A Q12879 8/20 0.43
GRIN2B Q13224 8/20 0.43
GRIN2C Q14957 8/20 0.43
GRIN3A Q8TCU5 8/20 0.43
PKM P14618 1/20 0.43
MAPT P10636 4/20 0.42
KDM4E B2RXH2 4/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
POLB P06746 2/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8121832 0.98 USP2 (0.47) USP2SMN1; SMN2ALOX15LMNAGRIN2D
SCHEMBL8120963 0.97 USP2 (0.44) USP2SMN1; SMN2ALOX15LMNAGRIN2D
SCHEMBL7265243 0.69 ALDH1A1 (0.49) SMN1; SMN2LMNAGRIN2DGRIN3BGRIN1
SCHEMBL8123253 0.69 USP2 (0.67) USP2SMN1; SMN2ALOX15LMNAPKM
SCHEMBL20681024 0.66 GRIN2D (0.37) LMNAGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL8124714 0.65 USP2 (1.00) USP2SMN1; SMN2ALOX15LMNAPKM
SCHEMBL6096035 0.65 GRIN2D (0.51) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL6701780 0.64 ACHE (0.40) USP2MAPTKDM4EMEN1KMT2A
SCHEMBL8113838 0.64 USP2 (0.97) USP2SMN1; SMN2ALOX15LMNAPKM
SCHEMBL7348559 0.63 SMN1; SMN2 (0.52) USP2SMN1; SMN2ALOX15LMNAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579359-B2 1-alkoxy 1H-imidazo ring systems and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2009-08-25 US disclosed
US-20090005376-A1 imidazonaphthyridines, imidazopyridines, imidazoquinolines, and imidazote-trahydroquinolines; immunomodulators for inducing cytokine biosynthesis; for treatment of viral and neoplastic diseases 3M INNOVATIVE PROPERTIES COMPANY 2009-01-01 US disclosed
US-7163947-B2 1-Amino 1H-imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-01-16 US disclosed
EP-0912564-B1 PROCESS FOR PREPARING TETRAHYDROIMIDAZOQUINOLINAMINES MINNESOTA MINING & MFG (US) 2003-01-08 EP disclosed
EP-0708773-B1 FUSED CYCLOALKYLIMIDAZOPYRIDINES MINNESOTA MINING & MFG (US) 2000-10-04 EP disclosed
US-5886006-A VIRICIDES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1999-03-23 US disclosed
US-5693811-A Process for preparing tetrahdroimidazoquinolinamines MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-12-02 US disclosed
US-5648516-A INTERFERON BIOSYNTHESIS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-07-15 US disclosed
US-5627281-A CHEMCAL INTERMEDIATES FOR VIRICIDES BY INDUCING SYNTHESIS OF INTERFERONS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-05-06 US disclosed
EP-0708773-A1 FUSED CYCLOALKYLIMIDAZOPYRIDINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1996-05-01 EP disclosed
US-5444065-A Viricides MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1995-08-22 US disclosed
WO-1995002598-A1 FUSED CYCLOALKYLIMIDAZOPYRIDINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1995-01-26 WO disclosed
US-5352784-A Viricides; immunomodulators MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1994-10-04 US disclosed
US-4031099-A ANTIALLERGENS BEECHAM GROUP LIMITED (EN) 1977-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005376-A1 imidazonaphthyridines, imidazopyridines, imidazoquinolines, and imidazote-trahydroquinolines; immunomodulators for inducing cytokine biosynthesis; for treatment of viral and neoplastic diseases IL2, IL4, IRF3 USP2 4037/4885SMN1; SMN2 3877/4885ALOX15 4222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.